Pembrolizumab: a key for some, but not all, HL

Saved in:
Bibliographic Details
Published in:Blood 2023-09, Vol.142 (10), p.861-862
Main Author: Cheah, Chan Y.
Format: Article
Language:English
Subjects:
Follow-Up Studies
Hodgkin Disease
Humans
Neoplasm Recurrence, Local
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c345t-183fda40f27a3d0aa2fd34a5c7ad62a3ddd8705dfc058443df306114b43ee35c3
container_end_page 862
container_issue 10
container_start_page 861
container_title Blood
container_volume 142
creator Cheah, Chan Y.
description
doi_str_mv 10.1182/blood.2023021050
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2862201012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712301457X</els_id><sourcerecordid>2862201012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-183fda40f27a3d0aa2fd34a5c7ad62a3ddd8705dfc058443df306114b43ee35c3</originalsourceid><addsrcrecordid>eNp1kDtPwzAUhS0EoqWwMyGPDE25fiVpN1TxkirBALPl2NdSIKnBTpDKryfQAhPTlY6-c6T7EXLKYMZYyS-qJgQ348AFcAYK9siYKV5mABz2yRgA8kzOCzYiRyk9AzApuDokI1HkRZ7PxZjMHrCtYmjqj7411YIa-oIb6kOkKbQ4pVXf0XXoqGmaKb1dHZMDb5qEJ7s7IU_XV4_L22x1f3O3vFxlVkjVZawU3hkJnhdGODCGeyekUbYwLudD5FxZgHLegiqlFM4LyBmTlRSIQlkxIefb3dcY3npMnW7rZLFpzBpDnzQvc86BAeMDClvUxpBSRK9fY92auNEM9Jcl_W1J_1kaKme79b5q0f0WfrQMwGIL4PDje41RJ1vj2qKrI9pOu1D_v_4JuIV0pA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2862201012</pqid></control><display><type>article</type><title>Pembrolizumab: a key for some, but not all, HL</title><source>ScienceDirect Journals</source><creator>Cheah, Chan Y.</creator><creatorcontrib>Cheah, Chan Y.</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2023021050</identifier><identifier>PMID: 37676693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Follow-Up Studies ; Hodgkin Disease ; Humans ; Neoplasm Recurrence, Local</subject><ispartof>Blood, 2023-09, Vol.142 (10), p.861-862</ispartof><rights>2023 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c345t-183fda40f27a3d0aa2fd34a5c7ad62a3ddd8705dfc058443df306114b43ee35c3</cites><orcidid>0000-0001-7988-1565</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000649712301457X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37676693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheah, Chan Y.</creatorcontrib><title>Pembrolizumab: a key for some, but not all, HL</title><title>Blood</title><addtitle>Blood</addtitle><subject>Follow-Up Studies</subject><subject>Hodgkin Disease</subject><subject>Humans</subject><subject>Neoplasm Recurrence, Local</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAUhS0EoqWwMyGPDE25fiVpN1TxkirBALPl2NdSIKnBTpDKryfQAhPTlY6-c6T7EXLKYMZYyS-qJgQ348AFcAYK9siYKV5mABz2yRgA8kzOCzYiRyk9AzApuDokI1HkRZ7PxZjMHrCtYmjqj7411YIa-oIb6kOkKbQ4pVXf0XXoqGmaKb1dHZMDb5qEJ7s7IU_XV4_L22x1f3O3vFxlVkjVZawU3hkJnhdGODCGeyekUbYwLudD5FxZgHLegiqlFM4LyBmTlRSIQlkxIefb3dcY3npMnW7rZLFpzBpDnzQvc86BAeMDClvUxpBSRK9fY92auNEM9Jcl_W1J_1kaKme79b5q0f0WfrQMwGIL4PDje41RJ1vj2qKrI9pOu1D_v_4JuIV0pA</recordid><startdate>20230907</startdate><enddate>20230907</enddate><creator>Cheah, Chan Y.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid></search><sort><creationdate>20230907</creationdate><title>Pembrolizumab: a key for some, but not all, HL</title><author>Cheah, Chan Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-183fda40f27a3d0aa2fd34a5c7ad62a3ddd8705dfc058443df306114b43ee35c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Follow-Up Studies</topic><topic>Hodgkin Disease</topic><topic>Humans</topic><topic>Neoplasm Recurrence, Local</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheah, Chan Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheah, Chan Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pembrolizumab: a key for some, but not all, HL</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2023-09-07</date><risdate>2023</risdate><volume>142</volume><issue>10</issue><spage>861</spage><epage>862</epage><pages>861-862</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37676693</pmid><doi>10.1182/blood.2023021050</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-09, Vol.142 (10), p.861-862
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_2862201012
source ScienceDirect Journals
subjects Follow-Up Studies
Hodgkin Disease
Humans
Neoplasm Recurrence, Local
title Pembrolizumab: a key for some, but not all, HL
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T14%3A07%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pembrolizumab:%20a%20key%20for%20some,%20but%20not%20all,%20HL&rft.jtitle=Blood&rft.au=Cheah,%20Chan%20Y.&rft.date=2023-09-07&rft.volume=142&rft.issue=10&rft.spage=861&rft.epage=862&rft.pages=861-862&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2023021050&rft_dat=%3Cproquest_cross%3E2862201012%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c345t-183fda40f27a3d0aa2fd34a5c7ad62a3ddd8705dfc058443df306114b43ee35c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2862201012&rft_id=info:pmid/37676693&rfr_iscdi=true